As of June 15, 2026, Health Canada no longer expects finished product specifications (FPS) to be submitted upfront with Class II and Class III NHP product licence applications (PLAs) or amendments. However, an FPS must still be established, maintained, and provided to Health Canada upon request.
Introduction
Health Canada has introduced an important process change for natural health product (NHP) licensing in Canada. As of June 15, 2026, finished product specifications, commonly referred to as an FPS, no longer needs to be submitted at the time of filing for Class II and Class III NHP PLAs and amendments.
This update was issued through Natural Health Product Licensing Bulletin No. 11, titled “Expectations for finished product specifications.” The change aligns Class II and Class III applications with the existing approach for Class I applications, where an FPS does not need to be submitted with the application but must still be established, maintained, and provided to Health Canada upon request.
For NHP brands, importers, licence holders, manufacturers, and regulatory teams, this is a meaningful procedural update. It may reduce the administrative burden at the point of filing, but it should not be misunderstood as a reduction in quality obligations. Health Canada is changing when an FPS is submitted and when they may be requested; it is not removing the requirement to establish and maintain them.
In practical terms, the update creates a more streamlined submission process while placing greater emphasis on internal regulatory readiness, quality documentation, and the ability to respond quickly if Health Canada issues an Information Request Notice (IRN).
At a Glance: Health Canada’s FPS Update for NHP Applicants
- As of June 15, 2026, an FPS, is no longer expected at the time of filing for Class II and Class III NHP PLA and amendment applications.
- The FPS remains part of the NHP quality and compliance framework. Licence holders must continue to establish and maintain an FPS in accordance with Health Canada’s quality expectations and provide them upon request.
- For applicants, the practical impact is a lighter submission package, not a lighter quality obligation. Companies should still prepare an FPS before submission, especially where the product involves complex ingredients, a Class III evidence package, higher-risk quality considerations, or a greater likelihood of an IRN.
- What Changed for Finished Product Specifications (FPS)?
- What Are Finished Product Specifications (FPS) for NHPs?
- Why This Update Matters for NHP Applicants
- Health Canada Can Still Request FPS During Review
- What NHP Licence Holders Should Do Now
- Common Misinterpretations of the FPS Update
- How SNI Supports NHP Applicants and Licence Holders
- Final Remarks
- FAQ: Health Canada FPS Requirements for NHPs
What Changed for Finished Product Specifications (FPS)?
Beginning June 15, 2026, applicants and licence holders are no longer expected to submit FPS with Class II and Class III PLAs or amendments.
Previous FPS Requirements
Previously, an FPS was a required part of the submission package for Class II and IIINHP applications. With this update, Health Canada has harmonized the FPS submission approach across Class I, Class II, and Class III applications.
The update means:
- Class I PLAs and amendments continue to follow the existing approach where FPS are not submitted at filing.
- Class II PLAs and amendments no longer require FPS submission at filing.
- Class III PLAs and amendments no longer require FPS submission at filing.
- FPS-only changes no longer need to be submitted as an amendment or notification to Health Canada.
- Health Canada may still request an FPS at any time, including during application review.
- This is a submission process change, not a change to the underlying quality obligation.
What Are Finished Product Specifications (FPS) for NHPs?
An FPS is the quality parameters used to confirm that an NHP meets the appropriate standards before it is released to the Canadian market. They outline the testing requirements, methods, tolerance limits, and acceptance criteria that apply to the finished product, and help support compliance with Health Canada’s NHP quality expectations.
In simpler terms, the FPS is one of the key documents that shows that the finished product is what it says it is, contains what it is supposed to contain, and meets the required quality (good manufacturing practices) standards before it is sold.
Common FPS Parameters for NHPs
For NHPs, an FPS may include parameters related to identity, quantity, purity, microbial contaminants, chemical contaminants, heavy metals, pesticides, residual solvents, disintegration, dosage form characteristics, and other product-specific quality criteria.
The exact specification package will depend on the product. For instance, a vitamin tablet, probiotic, botanical extract capsule, topical product, or sterile NHP will all carry different quality profiles and risk considerations. As such, the FPS should be tailored to the formulation, dosage form, ingredients, route of administration, and intended conditions of use.
Impact of the FPS Update on Product Compliance
Although applicants are no longer required to submit a copy of the FPS with a PLA or amendment, the product must still meet all applicable quality requirements before it is released to the Canadian market.
An FPS should therefore remain part of the supporting quality documentation and be available if Health Canada requests them.
Why This Update Matters for NHP Applicants
For NHP applicants, this update may help streamline the filing process for Class II and Class III PLAs and amendments. With the FPS no longer expected at the time of filing, applicants may be able to submit a cleaner application package; however, the quality file should still be ready to support the product under review.
FPS Still Belongs in the Internal Quality File
Applicants should continue to treat the FPS as part of the internal quality file, even thought it is no longer included in the initial application package.
Quality Considerations for Higher-Risk NHPs and Class III Applications
This is especially important for products where quality considerations may be more complex, including higher-risk NHPs and many Class III applications. These products often rely on a more detailed safety, efficacy, and quality rationale, and may involve additional evidence to support the proposed formulation, conditions of use, or claim structure.
Aligning Finished Product Testing with the Evidence Package
In those cases, finished product testing should align with the methodologies, specifications, and quality parameters reflected in the evidence package and applicable quality requirements. A complete and well-supported FPS can help demonstrate that the finished product is consistent with the product being assessed and can support an efficient response if Health Canada issues an IRN during review.
Health Canada Can Still Request FPS During Review
Health Canada may still request an FPS during the review of a PLA or amendment where risk-related quality issues are identified. In these cases, the request would be issued through an IRN.
Cannabis-Containing NHPs and Other Quality Considerations
The bulletin specifically identifies cannabis-containing NHPs as one example where an FPS may be requested. However, Health Canada also notes that risk-related quality issues may vary by submission and may evolve as scientific knowledge and product innovation advance.
Why Product Complexity Still Matters
This is particularly relevant for products with more complex quality considerations, including novel dosage forms, complex ingredient combinations, modified delivery systems, botanical extracts, or ingredients with known contaminant concerns.
Class III Applications and Quality Readiness
For Class III applications, the quality file should remain aligned with the broader safety, efficacy, and quality rationale used to support the submission. Where the FPS reflects testing methods, acceptance criteria, or quality parameters relied on in the evidence package, having it prepared can make it easier to respond if Health Canada requests additional quality information.
What NHP Licence Holders Should Do Now
NHP licence holders should review their internal procedures to ensure the new Health Canada approach is reflected in their regulatory and quality workflows. This includes confirming that FPS are established for each licensed or proposed NHP, aligned with the current Quality of Natural Health Products Guide, and appropriate for the product’s formulation, dosage form, ingredients, and intended conditions of use.
Maintain a Defensible Product Quality File
Companies should ensure that the FPS remains scientifically justified, version-controlled, and maintained as part of the product quality file. Supporting documentation should also be kept current, including the rationale for test methods, tolerance limits, acceptance criteria, and any product-specific quality considerations.
Assess FPS Changes Before Treating Them as Non-Notifiable
Licence holders should also have a clear internal process for assessing FPS updates before treating them as non-notifiable. A change may appear limited to the FPS, but it should still be reviewed to confirm that it does not affect licensed product details, label information, formulation, Good Manufacturing Practices (GMP) and procedures, or other requirements that may trigger a notification and/or amendment.
This update gives licence holders an opportunity to streamline filing, provided internal review processes remain robust enough to confirm whether an FPS change is truly non-notifiable and whether the supporting quality file is ready for inspection or review.
Common Misinterpretations of the FPS Update
FPS Are Still Required for NHP Compliance
One of the most important distinctions is that the FPS is no longer expected at filing, but they have not been removed from the NHP quality framework. Licence holders should still ensure that specifications are established, maintained, and available if Health Canada requests them.
Quality Review May Still Apply Where Risk Is Identified
The update should not be read as Health Canada stepping away from quality review. Where risk-related quality issues are identified during a Class II or Class III application or amendment review, Health Canada may still request an FPS through an IRN.
FPS-Only Changes Should Still Be Assessed Carefully
Only changes limited solely to the FPS are non-notifiable under this update. If a change affects licensed product information, formulation details, conditions of use, claims, risk statements, dosage form, ingredient information, label content, or another regulated aspect of the product, a notification or amendment may still be required.
For example, a change to an ingredient standardization may appear to be a specification update at first glance. However, if that standardization is reflected in the product licence or affects the product’s characterization, potency, quality rationale, or evidence alignment, it should not be treated as an FPS-only change. In that case, the change may still require an amendment or an entirely new product licence.
FPS Should Not Be Prepared Only After Licensing
An FPS should still be prepared early enough to support internal decision-making and a timely response if Health Canada requests additional quality information.
Early preparation also reduces the risk of delays during review and helps ensure the product quality file is complete before questions arise.
How SNI Supports NHP Applicants and Licence Holders
Source Nutraceutical, Inc. (SNI) supports NHP companies with Canadian regulatory strategy, PLAs, FPS creation and reviews, quality documentation assessments, and post-licence compliance.
Following Health Canada’s June 2026 FPS update, companies may need support determining whether their FPS are complete, whether a proposed change is truly FPS-only, and whether the product quality file is ready if Health Canada requests additional information during review.
NHP Product Licence Application (PLA) Strategy
SNI supports Class I, Class II, and Class III NHP PLAs, including submission strategy, evidence alignment, product-specific quality considerations, and regulatory pathway assessment. This includes reviewing whether the product specifications, formula records, labels, claims, and supporting documentation align before submission.
Finished Product Specification (FPS) and Quality File Review
Our team can conduct an FPS gap assessment against Health Canada’s current quality expectations, including review of test methods, acceptance criteria, tolerance limits, product-specific quality parameters, and alignment with the product being licensed.
FPS Changes, IRNs, and Post-Licence Compliance
SNI can also support licence holders in determining whether a proposed change is limited to an FPS or whether it may trigger a notification, amendment, or other regulatory action. Where Health Canada requests an FPS or additional quality information during review, SNI can assist with IRN response strategy, regulatory rationale, and alignment with applicable GMP expectations under GUI-0158.
Book an introductory call using the following form:
Final Remarks
Health Canada’s June 15, 2026 update removes the expectation to submit an FPS with Class II and Class III NHP PLAs and amendments. It also confirms that changes limited solely to an FPS no longer need to be submitted as an amendment or notification.
While the bulletin is framed as a product licensing process change, its practical effect is a shift in where FPS oversight sits in daily operations. Rather than treating the FPS as a document managed primarily through the product licence application process, licence holders will need to manage it more actively within the quality system. The FPS should remain part of a defensible product quality file, supported by appropriate QA controls, version history, testing rationale, and GMP-aligned release procedures.
For industry, the update may reduce what needs to be submitted upfront, but it does not reduce the need for regulatory judgement or quality readiness. Companies should use the change to streamline submissions while keeping the FPS current, justified, and aligned with the broader compliance file.
FAQ: Health Canada FPS Requirements for NHPs
Do finished product specifications (FPS) still need to be prepared for NHPs?
Yes. The update changes when FPS is submitted, not whether it needs to be established and maintained.
FPS is no longer expected at the time of filing for Class II and Class III NHP product licence applications or amendments. However, licence holders must still ensure that an FPS is prepared, maintained as part of the product quality file, and available to Health Canada upon request.
Do FPS need to be submitted with Class II NHP applications?
No. As of June 15, 2026, an FPS no longer needs to be submitted at the time of filing for Class II NHP PLAs or amendment applications.
Do FPS need to be submitted with Class III NHP applications?
No. As of June 15, 2026, an FPS no longer needs to be submitted at the time of filing for Class III NHP PLAs or amendment applications. However, Health Canada may still request FPS during review if a risk-related quality issue is identified.
Are FPS-Only Changes Still Notifiable to Health Canada?
No. Changes limited solely to the FPS no longer require an amendment or notification to Health Canada. Companies should still document the change internally and confirm that it does not affect licensed product information or other regulatory obligations.
Can Health Canada still request finished product specifications (FPS)?
Yes. Health Canada can request an FPS for any NHP at any time. If an FPS is requested during application review, they will be requested through an IRN. Applicants should prepare an FPS early enough to avoid developing core quality documentation under an IRN response timeline.
Does this update change NHP GMP requirements?
No. The update does not change NHP GMP requirements. Regulated parties must continue to comply with applicable GMP requirements, including those outlined in GUI-0158.
What should companies do before removing FPS from their submission package?
Companies should confirm that the FPS is removed from the submission package only where appropriate, while retaining them in the product quality file for review if requested during or after licensing. They should also confirm that any related changes do not affect licensed product information, formulation details, label content, or other regulated elements that may still require a notification or amendment.
The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.
